Key Facts

Invested since 2019
Based in International

About the company

VACIS is the leading tissue engineering company for body-own blood vessels.
The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.

Do you want to

know more about this company?

Zum Artikel

Dr. Christian Kannemeier Senior Investment Manager

Dr. Christian KannemeierSenior Investment Manager

Vacis in the news

Zum Artikel

Press

10. October 2019

Vacis raises capital from Brightlands Venture Partners, HTGF, LIOF and RVO

More startups from Life Sciences